Organization
Sanofi
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Sanofi
... Paris, France and South San Francisco, Calif - Sanofi will develop Principia Biopharma Inc.'s experimental oral treatment that shows promise in ...
... Sanofi, Principia agree to develop multiple sclerosis drug candidate - Clinical-stage oral drug ...
... therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today positive complete results from the APOLLO Phase 3 study of ...
... neurologists, the report covers 12 major therapies from Genzyme, Biogen, Bayer, Teva, Sanofi, Novartis, Roche, EMD Serono, and AbbVie/Biogen. Top Takeaways Barriers affect just under ...
... Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Alnylam present positive complete results from ...
... Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and ...
... severe gout. Most recently, he served as Vice President and Head of Sanofi/Genzyme's North American Rheumatology Business Unit, where he led the development of commercialization ...
... CAMBRIDGE, Mass. - Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today new investigational data that suggest slowing of cortical gray matter ...
... Sanofi Genzyme , the specialty care global business unit of Sanofi , announced today that relapsing remitting multiple sclerosis (RRMS) patients who received ...
... Sanofi Genzyme , the specialty care global business unit of Sanofi , announced today new investigational data that suggest slowing of cortical gray ...
... severe gout. Most recently, he served as Vice President and Head of Sanofi/Genzyme's North American Rheumatology Business Unit, where he led the development of commercialization ...
... But they likely won’t be alone when bidding kicks off. Companies including Sanofi, Johnson & Johnson and Procter & Gamble could also look to snag ...
... we need to pursue our plans.” RELATED: Impact bags $22M to save ex-Sanofi drug from trial limbo That represents a whiplash turnaround for fedratinib, albeit ...
... Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that new investigational data on its marketed treatments for relapsing ...
... mechanistic modeling to drug research and development, today announced a collaboration with Sanofi to develop quantitative systems pharmacology (QSP) models in immuno-oncology. Applied BioMath will ...
... Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients ...
... a Series A financing. Impact was formed in 2016 after acquisition of Sanofi's full rights for the global development and commercialization of fedratinib. The majority ...
... and worldwide chairman of pharmaceuticals, Joaquin Duato, as PhRMA board chairman; and Sanofi CEO Olivier Brandicourt will become chairman-elect; both effective next February. Release > ...
... Sanofi’s flu vaccines are the top-selling in the world. To meet demand for ...
... healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines ...
... the U.S. - Paris, France and Tarrytown, N.Y., October 5, 2017 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Court of Appeals ...
... To defend against Amgen’s claim that Sanofi and Regeneron had infringed one of its patents with new atopic dermatitis ...
... Paris, France - Sanofi has appointed Stefan Oelrich as Executive Vice President Diabetes & Cardiovascular (DCV), ...
... Alzheimer's disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University ...
... demonstrated, thereby cutting down initial R&D expenditure. For instance, in January 2014, Sanofi and Alnylam signed an agreement for the development of treatment therapies for ...
... before the company was sold in 2011 to the French drug giant Sanofi SA for more than $20 billion. In an interview with the Globe ...
... Paris, France and Tarrytown, New York - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the European Commission has granted ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤